SG11202105746TA - Methods for imaging and treatment of somatostatin-receptor positive tumors - Google Patents

Methods for imaging and treatment of somatostatin-receptor positive tumors

Info

Publication number
SG11202105746TA
SG11202105746TA SG11202105746TA SG11202105746TA SG11202105746TA SG 11202105746T A SG11202105746T A SG 11202105746TA SG 11202105746T A SG11202105746T A SG 11202105746TA SG 11202105746T A SG11202105746T A SG 11202105746TA SG 11202105746T A SG11202105746T A SG 11202105746TA
Authority
SG
Singapore
Prior art keywords
somatostatin
imaging
treatment
methods
receptor positive
Prior art date
Application number
SG11202105746TA
Other languages
English (en)
Inventor
Andreas G Moraitis
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of SG11202105746TA publication Critical patent/SG11202105746TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SG11202105746TA 2018-12-20 2019-12-19 Methods for imaging and treatment of somatostatin-receptor positive tumors SG11202105746TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862783015P 2018-12-20 2018-12-20
PCT/US2019/067341 WO2020132171A1 (en) 2018-12-20 2019-12-19 Methods for imaging and treatment of somatostatin-receptor positive tumors

Publications (1)

Publication Number Publication Date
SG11202105746TA true SG11202105746TA (en) 2021-07-29

Family

ID=71101898

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105746TA SG11202105746TA (en) 2018-12-20 2019-12-19 Methods for imaging and treatment of somatostatin-receptor positive tumors

Country Status (11)

Country Link
US (1) US20220062386A1 (he)
EP (1) EP3897629A4 (he)
JP (1) JP7444889B2 (he)
KR (1) KR20210107004A (he)
CN (1) CN113194944A (he)
AU (1) AU2019405771A1 (he)
CA (1) CA3122581A1 (he)
IL (1) IL284237A (he)
MX (1) MX2021007402A (he)
SG (1) SG11202105746TA (he)
WO (1) WO2020132171A1 (he)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230071889A1 (en) * 2018-12-21 2023-03-09 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
WO2024054785A2 (en) * 2022-09-06 2024-03-14 Corcept Therapeutics Incorporated Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to selective glucocorticoid receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3338781T3 (pl) 2012-05-25 2020-03-31 Corcept Therapeutics Incorporated Modulatory receptorów glukokortykoidowych typu azadekaliny skondensowanej z heteroaryloketonem
US8859774B2 (en) * 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
EP3265127B1 (en) 2015-03-02 2024-02-21 Corcept Therapeutics, Inc. Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor
CN108137690A (zh) * 2015-06-25 2018-06-08 高级催化剂应用品有限公司 治疗过度表达生长抑素受体的神经内分泌肿瘤的方法
CN110475558A (zh) * 2017-03-09 2019-11-19 科赛普特治疗学股份有限公司 糖皮质激素受体调节剂在儿茶酚胺分泌型肿瘤治疗中的应用
US10946005B2 (en) * 2018-11-09 2021-03-16 Corcept Therapeutics Incorporated Methods for shrinking pituitary tumors

Also Published As

Publication number Publication date
JP2022515233A (ja) 2022-02-17
KR20210107004A (ko) 2021-08-31
CN113194944A (zh) 2021-07-30
CA3122581A1 (en) 2020-06-25
US20220062386A1 (en) 2022-03-03
AU2019405771A1 (en) 2021-06-17
IL284237A (he) 2021-08-31
WO2020132171A1 (en) 2020-06-25
MX2021007402A (es) 2021-07-15
JP7444889B2 (ja) 2024-03-06
EP3897629A4 (en) 2022-12-07
EP3897629A1 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
IL280707A (he) שיטות דיאגנוסטיות ותרפויטיות לטיפול בסרטן השד
IL269027A (he) טיפול בגידולים שמבטאים lag-3
IL280899A (he) תרכובות הטרוציקליות להדמייה וטיפול בסרטן ושיטות לשימוש בהן
GB201703769D0 (en) Imaging apparatus and method of imaging
IL276808A (he) תכשירים ושיטות לטיפול בסרטן
GB201804514D0 (en) Treatment of pyroptosis
EP3099325A4 (en) Methods of treating and imaging tumor micrometastases using photoactivatable immunoconjugates
IL286297A (he) שיטות לטיפול סרטן שאריות מינימלי
SG11202011117VA (en) Treatment of cancer
IL283511A (he) דנדרימר ושימוש בו לטיפול והדמיה
SG11202010793UA (en) Methods of treating cancer
IL284237A (he) הדמיה של וטיפול בגידולים המבטאים רצפטור סומסטאטין
IL277981A (he) שיטות לטיפול בסרטן
GB201804515D0 (en) Treatment of necroptosis
GB201820994D0 (en) Methods of treatment and diagnosis of tumours
SG11202011434SA (en) Methods for the treatment of bladder cancer
EP3621619C0 (en) COMPOUNDS AND METHODS FOR TREATMENT OF VITAL PAIN
ZA202105583B (en) Methods of diagnosing and treating cervical cancer
IL282485A (he) שיטות לטיפול בגידולי p53 wt
IL280262A (he) הרכבים ושיטות לטיפול בסרטן
GB201820975D0 (en) Methods of cancer treatment
EP3148468B8 (en) Apparatus for stimulation and/or treatment of anatomical tissues
IL271307A (he) שיטות לטיפול בגידולי מוח באמצעות טיפול משולב
IL271309A (he) שיטות לטיפול בגידולי מוח באמצעות טיפול משולב
GB201820098D0 (en) Methods of cancer treatment